MedCity News August 21, 2024
Lifestyle is equally important for long-term success. A good behavior-change program can benefit many people with chronic conditions – whether by impacting clinical outcomes, improving quality of life, or helping to lower long-term health-care costs.
GLP-1-based agonists (GLP-1s) are transforming the obesity treatment landscape and the positive results keep rolling in. In the last 12 months, there’s been a series of high-profile papers and clinical trials which have demonstrated GLP-1s to prevent or reverse prevalent chronic conditions such as sleep apnea, fatty liver, and CVD. Creating the potential possibility of prescribing these medications beyond the purpose of weight loss and expanding the FDA-approved indications.
First, a (very) brief history on GLP-1s: These medications, which mimic the hormone (GLP-1) that...
Today's Sponsors
Today's Sponsor